Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MONOKET vs NITRO IV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase c GMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Acute angina pectoris,Prophylaxis of angina (before exercise or stress),Congestive heart failure (acute),Controlled hypotension during surgery,Hypertensive emergencies (off-label),Pulmonary edema (off-label)
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Nitroglycerin is extensively metabolized in the liver by glutathione S-transferases and, to a lesser extent, by arterial walls. It undergoes denitration to form 1,2- and 1,3-glyceryl dinitrate, which have weaker vasodilatory activity.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
60% bound to albumin.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
3-4 L/kg (high, due to extensive tissue uptake, especially vascular smooth muscle).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
IV: 100% (not administered via other routes due to extensive first-pass metabolism).
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, consider dose reduction due to risk of methemoglobinemia and cyanide toxicity, monitor closely.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or use with extreme caution, reduce dose by 75%.
Safety and efficacy have not been established in pediatric patients (age <18 years).
0.25-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5-1 mcg/kg/min every 3-5 minutes; maximum 5 mcg/kg/min for children.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Initiate at lower end of dosing range (5 mcg/min) due to increased sensitivity; titrate slowly with careful hemodynamic monitoring.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Nitroglycerin is contraindicated in patients with severe anemia, increased intracranial pressure, or those using phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypotension and reflex tachycardia may occur; monitor blood pressure,May exacerbate angina from abrupt discontinuation (tolerance and rebound),Caution in patients with hypovolemia, right ventricular infarction, or hypertrophic cardiomyopathy,Avoid in patients with constrictive pericarditis or pericardial tamponade,May cause methemoglobinemia, especially with high doses or prolonged use
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Allergy to nitroglycerin or nitrates,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Concomitant use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil),Hypotension (systolic BP < 90 mm Hg),Right ventricular infarction,Constrictive pericarditis,Pericardial tamponade
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
No specific food restrictions. Avoid alcohol as it may enhance vasodilation and hypotension.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal harm at high doses. Second/third trimester: Potential risk of fetal bradycardia and hypotension; use only if clearly needed. Avoid near term due to risk of uterine relaxation and hemorrhage.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
Unknown excretion in human milk. M/P ratio not established. Short half-life suggests minimal exposure; however, use with caution and consider risk of infant hypotension.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
No standard dose adjustment in pregnancy. Consider higher initial doses due to increased volume of distribution and clearance, but titrate to effect due to potential for heightened sensitivity.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Use non-PVC infusion sets to minimize drug adsorption. Monitor for hypotension, especially with concurrent PDE-5 inhibitor use. Tolerance can develop with prolonged infusion; use lowest effective dose. Do not abruptly discontinue after prolonged use to avoid rebound ischemia. Avoid in patients with right ventricular infarction or severe aortic stenosis.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
Report any severe headaches, dizziness, or fainting during infusion.,Avoid taking erectile dysfunction medications like sildenafil or tadalafil while on this treatment.,Notify your healthcare provider if you have a history of low blood pressure or recent heart attack.,The medication will be given by a healthcare professional and vital signs will be monitored closely.,Do not stop the infusion suddenly without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MONOKET vs NITRO IV, answered by our medical review team.
MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. NITRO IV is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase c GMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MONOKET and NITRO IV depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. The standard adult dose of NITRO IV is: Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MONOKET and NITRO IV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. NITRO IV is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal harm at high doses. Second/third trimester: Potential risk of fetal bradycardia and hypoten. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.